Tirzepatide and Retatrutide: a new generation of multi-receptor incretins

A review of the published Phase 3 evidence for tirzepatide (SURPASS, SURMOUNT) and the Phase 2 results for retatrutide, highlighting the magnitude of weight loss, glycemic control, and emerging cardiometabolic benefits reported in peer-reviewed trials.